



## **Avenge Bio to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37<sup>th</sup> Annual Meeting**

NATICK, Mass., October 19, 2022 - Avenge Bio, Inc. (“Avenge” or the “Company”), a biotechnology company developing the LOCOcyte™ Immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced that three abstracts were selected for presentation as posters at the Society of Immunotherapy of Cancer (SITC) 37<sup>th</sup> Annual Meeting on November 10-11, 2022, at the Boston Convention & Exhibition Center – Exhibit Hall C, Boston, MA.

Avenge’s most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. AVB-001, developed in the LOCOcyte™ platform, consists of proprietary engineered human cells. The cells are encapsulated in a pro-inflammatory biomaterial that are delivered to the local tumor environment and generate high, sustained concentrations of native IL-2. The encapsulated cells initiate a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge has additional pipeline candidates for the treatment of a wide range of cancers including pancreatic, lung and breast cancers. In July 2022, Avenge announced that Food and Drug Administration (“FDA”) cleared the Investigational New Drug (“IND”) application for AVB-001 for the treatment of platinum resistance ovarian cancer. The Phase 1, multicenter clinical trial is expected to be initiated in Q4 2022.

### **Details on Avenge’s presentations at SITC are as follows:**

#### **Abstract #: 363**

**Poster Title:** Localized interleukin-2 cytokine factories eradicate mesothelioma tumors via activation of adaptive and innate immune cells

**Presenting Author:** Samira Aghlara-Fotovvat, BA (Rice University)

**Location:** Poster Hall C

**Date:** Thursday, November 10, 2022

**Time:** 11:40 AM-1:10 PM ET & 7:30-9:00 PM ET

#### **Abstract #: 1095**

**Poster Title:** IL-12-Based Cytokine Factories Modulate Tumor Microenvironment to Eradicate Pancreatic Tumors in Mice and are Well Tolerated in Non-human Primate

**Presenting Author:** Amanda Nash, BS (Rice University)

**Location:** Poster Hall C

**Date:** Thursday, November 10, 2022

**Time:** 11:40 AM-1:10 PM ET & 7:30-9:00 PM ET

#### **Abstract #: 1094**

**Poster Title:** Favorable preclinical efficacy and safety profile of AVB-001 a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first in human clinical development

**Presenting Author:** Guillaume Carmona, PhD (Avenge Bio, Inc.)

**Location:** Poster Hall C

**Date:** Friday, November 11, 2022

**Time:** 11:55 AM-1:25 PM ET & 7:00-8:30 PM ET

The posters will be available on the Presentations and Publications section of [www.avengebio.com](http://www.avengebio.com) following the conference.

### **About LOCOcyte™ Platform**

Our LOCOcyte™ allogeneic cell-based immunotherapy platform enables potent localized modulation of the immune system which also precipitates a systemic immune response, allowing us to treat previously intractable cancers. The technology leverage three unique advantages:

- (1) Potent immune effector molecules are generated by synthetically engineering allogeneic cells creating a ready-to-use therapy,
- (2) Therapy is localized in proximity to the primary tumor site and generates innate and adaptive immune response, and
- (3) The immunomodulator trains the patient's immune system generating a robust immune response that seeks and eradicates distal metastasis without systemic toxicity.

### **About Avenge Bio**

Avenge Bio, Inc. ("Avenge") is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyte™ platform. The LOCOcyte™ platform leverages proprietary engineered cells delivered to the local tumor environment that generate high concentrations of immune effector molecules in proximity to the tumor. This initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. Avenge has additional pipeline candidates for the treatment of a wide range of cancers including pancreatic, lung and breast cancers. Avenge was founded in 2019 base upon technology developed in the laboratory of Omid Veisheh, Ph.D. and has an exclusive license from Rice University for this technology. To learn more about Avenge visit: [www.avegenbio.com](http://www.avegenbio.com) and follow us on [LinkedIn](#) and [Twitter](#).

#### **Media Contact:**

Angela Lam  
Avenge Bio, Inc.  
Email: [Angela.Lam@avegenbio.com](mailto:Angela.Lam@avegenbio.com)

#### **Investor Contact:**

Doug Carlson  
Avenge Bio, Inc.  
Email: [Doug.Carlson@avegenbio.com](mailto:Doug.Carlson@avegenbio.com)